IntraBio
Jim Meyers has extensive work experience in the pharmaceutical and biotech industry. Jim is currently serving as the President & CEO of IntraBio Ltd. Since 2020. Prior to this, they worked as a Senior Advisor at the Boston Consulting Group (BCG) starting in 2019. Jim also served as a Board Member for Sangamo Therapeutics, Inc., CytomX Therapeutics, Arbutus Biopharma Corporation, and Pulmocide. Additionally, Jim Meyers has held various senior positions at Gilead Sciences, including Executive Vice President of the Worldwide Commercial Organization. Jim also worked at Astra Pharmaceuticals and Stuart Pharmaceuticals, where they gained experience in sales, training, and sales management.
Jim Meyers attended Boston College from 1982 to 1986, where they earned a Bachelor's degree in Economics.
This person is not in any teams
This person is not in any offices
IntraBio
IntraBio is a biopharmaceutical company with a late-stage drug pipeline that includes novel treatments for genetic and neurodegenerative diseases.Their clinical programs leverage the expertise of their scientific founders from the University of Oxford and University of Munich, the preeminent experts and pioneers in discovering and developingsmall molecule drugs that modulate lysosomal function and intracellular calcium signaling.Their management team and business consultants have vast commercial and regulatory experience in drug product development, including all stages from small molecule manufacturing, clinical studies, and regulatory approvals in the USA and Europe.With their successful track record of drug development and commercialization, IntraBio’s team translates research in the fields of lysosomal biology, autophagy, and neurology into orphan drugs and treatments that will significantly improve the lives of patients, their caregivers, and families.